☰
Mechanisms Drugs Diseases Blog About

155 CLL Clinical Trials Recruiting Now (July 2026): Chronic Lymphocytic Leukemia — BTK Inhibitors, BTK Degraders, Venetoclax, BCL-2, Acalabrutinib

Last updated: July 1, 2026

Answer a few questions to find clinical trials matched to your specific Chronic Lymphocytic Leukemia situation.

Usually 2–3 minutes. No sign-up.

Find matching trials →

Current Clinical Trial Landscape

Active research areas in 2026:

Standard of care: First-line: BTK inhibitor continuous (ibrutinib, acalabrutinib, zanubrutinib) OR fixed-duration venetoclax + obinutuzumab. Second-line: sequence depends on first-line — venetoclax after BTKi, or BTKi after venetoclax. del(17p)/TP53 and IGHV status guide treatment choice.

Recruiting Trials by Treatment Setting

Treatment-Naïve (First-Line)

Testing next-gen agents and fixed-duration combos as first-line:

Relapsed / Refractory — After BTK Inhibitor

After covalent BTK inhibitor failure — non-covalent BTKi, BTK degraders, and BCL-2 combos:

Next-Gen BCL-2 Combinations

Sonrotoclax and lisaftoclax aim to replace venetoclax with better efficacy/safety:

Early Treatment (High-Risk CLL)

Treating early in patients with high-risk genetics or infection risk, before standard IWCLL treatment criteria are met:

Bispecific Consolidation & Richter Transformation

No Phase 3 currently recruiting in either subspace as of July 2026 — multiple Phase 3 trials (surovatamig consolidation, pirtobrutinib + standard treatment for Richter, sonrotoclax + zanubrutinib including Richter) are filed as NOT_YET_RECRUITING and expected to open in coming months. Earlier-phase Richter trials may be available; search the full CLL trial list below for current options.

Showing selected notable trials. View all 155 recruiting interventional trials on ClinicalTrials.gov (corpus count, July 2026).

Frequently Asked Questions

How do I find CLL clinical trials I'm eligible for?

Enter your CLL details into ClinTrialFinder — including del(17p)/TP53 status, IGHV mutation status, prior BTK inhibitor and venetoclax exposure, and Rai/Binet stage. The AI matches you with trials in minutes.

What CLL trials are currently recruiting?

There are 155 recruiting interventional trials for CLL in July 2026 including 21 Phase 3 studies. Recent Phase 3: sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + acalabrutinib NCT07277231, BGB-16673 BTK degrader vs pirtobrutinib NCT06973187, APG2575 global trial NCT06104566, early treatment for high-risk CLL NCT04269902, pirtobrutinib vs ibrutinib NCT05254743, sonrotoclax + zanubrutinib SoNRise NCT07321652. Active classes: next-gen BTK inhibitors (pirtobrutinib, rocbrutinib, DZD8586), BTK degraders (BGB-16673), BCL-2 combinations (sonrotoclax, lisaftoclax, APG2575), acalabrutinib + venetoclax fixed-duration, and early treatment for high-risk or high-infection-risk CLL.

Find CLL Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.

Find Matching Trials

Related Disease Trials

Non-Hodgkin Lymphoma Trials Acute Myeloid Leukemia (AML) Clinical Trials Multiple Myeloma Trials Waldenström's Macroglobulinemia Trials All Disease Trials

Learn More

What Information Do You Need for a Clinical Trial Search? How We Rank Trials: Evidence-Informed Scoring Our Guided Questionnaire: Answer Questions, Find Trials

This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or healthcare team. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.